FDA accepts for priority review New Drug Application for voclosporin for lupus nephritis
Priority review designation for voclosporin (a novel calcineurin inhibitor) is supported by data from the phase 3 AURORA and phase 2 AURA-LV studies.
Source:
Biospace Inc.